Published in J Neurooncol on August 06, 2010
Management of large and giant vestibular schwannomas. Skull Base (2011) 0.91
Outcome on hearing and facial nerve function in microsurgical treatment of small vestibular schwannoma via the middle cranial fossa approach. Eur Arch Otorhinolaryngol (2012) 0.82
Preoperative detection of the facial nerve by high-field magnetic resonance imaging in patients with vestibular schwannoma. Neuroradiology (2013) 0.78
Facial functional outcome in monitored versus not-monitored patients in vestibular schwannomas surgery. Asian J Neurosurg (2016) 0.75
Anterior Extension of Tumor is as Important as Tumor Size to Facial Nerve Outcome and Extent of Resection for Vestibular Schwannomas. J Neurol Surg B Skull Base (2017) 0.75
Prognostic Indices for Predicting Facial Nerve Outcome following the Resection of Large Acoustic Neuromas. J Neurol Surg B Skull Base (2017) 0.75
Facial nerve grading system. Otolaryngol Head Neck Surg (1985) 9.72
Improved preservation of hearing and facial nerve function in vestibular schwannoma surgery via the retrosigmoid approach in a series of 200 patients. J Neurosurg (2006) 2.62
Vestibular schwannoma: surgery or gamma knife radiosurgery? A prospective, nonrandomized study. Neurosurgery (2009) 1.77
Facial nerve injury in acoustic neuroma (vestibular schwannoma) surgery: etiology and prevention. J Neurosurg (1997) 1.72
Beyond audiofacial morbidity after vestibular schwannoma surgery. J Neurosurg (2009) 1.59
Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery (1997) 1.53
Management of 1000 vestibular schwannomas (acoustic neuromas): hearing function in 1000 tumor resections. Neurosurgery (1997) 1.46
Goodness-of-fit processes for logistic regression: simulation results. Stat Med (2002) 1.30
A comprehensive analysis of hearing preservation after radiosurgery for vestibular schwannoma. J Neurosurg (2010) 1.11
Hearing preservation after stereotactic radiosurgery for vestibular schwannoma: a systematic review. J Clin Neurosci (2009) 0.98
Facial nerve motor-evoked potential monitoring during skull base surgery predicts facial nerve outcome. J Neurol Neurosurg Psychiatry (2008) 0.97
The natural history of untreated sporadic vestibular schwannomas: a comprehensive review of hearing outcomes. J Neurosurg (2010) 0.96
Assessing impairment and disability of facial paralysis in patients with vestibular schwannoma. Arch Otolaryngol Head Neck Surg (2007) 0.94
Molecular biology of familial and sporadic vestibular schwannomas: implications for novel therapeutics. J Neurosurg (2009) 0.93
Conservative management of vestibular schwannomas: an effective strategy. Laryngoscope (2008) 0.91
Facial nerve monitoring parameters as a predictor of postoperative facial nerve outcomes after vestibular schwannoma resection. Otol Neurotol (2005) 0.88
Radiobiology of vestibular schwannomas: mechanisms of radioresistance and potential targets for therapeutic sensitization. Neurosurg Focus (2009) 0.87
Facial nerve preservation after vestibular schwannoma Gamma Knife radiosurgery. J Neurooncol (2009) 0.86
Predictive factors of long-term facial nerve function after vestibular schwannoma surgery. Otol Neurotol (2002) 0.85
Acoustic neurinoma in the elderly: factors predictive of postoperative outcome. Neurosurgery (1992) 0.85
Intraoperative monitoring and facial nerve outcomes after vestibular schwannoma resection. Otol Neurotol (2003) 0.85
Predicting long-term facial nerve outcome after acoustic neuroma surgery. Otolaryngol Head Neck Surg (1993) 0.82
Facial nerve outcome after microsurgical resection of vestibular schwannoma. Prog Neurol Surg (2008) 0.82
Non-audiofacial morbidity after Gamma Knife surgery for vestibular schwannoma. Neurosurg Focus (2009) 0.81
Long-term facial nerve clinical evaluation following vestibular schwannoma surgery. Arq Neuropsiquiatr (2008) 0.79
[Complete facial palsy following surgery for acoustic nerve neurinoma: evolution and associated ophthalmological complications]. Acta Otorrinolaringol Esp (2008) 0.79
An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg (2011) 6.32
Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature (2004) 5.85
Clinical trials in head injury. J Neurotrauma (2002) 4.34
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg (2010) 2.42
Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg (2010) 2.19
Modern surgical outcomes following surgery for sphenoid wing meningiomas. J Neurosurg (2013) 2.16
Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology (2009) 2.15
Complications of lumboperitoneal shunts. Neurosurgery (2007) 2.07
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol (2012) 2.04
Cerebrospinal fluid leak after acoustic neuroma surgery: a comparison of the translabyrinthine, middle fossa, and retrosigmoid approaches. Otol Neurotol (2003) 1.87
Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res (2013) 1.86
Factors affecting outcome following treatment of patients with cavernous sinus meningiomas. J Neurosurg (2010) 1.74
Surgical technique of temporary arterial occlusion in the operative management of spinal hemangioblastomas. World Neurosurg (2010) 1.72
Posttreatment prognosis of patients with esthesioneuroblastoma. J Neurosurg (2010) 1.67
The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. J Neurosurg (2010) 1.67
Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. J Neurosurg (2011) 1.67
Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg (2008) 1.66
Cancer and the complement cascade. Mol Cancer Res (2010) 1.64
Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg (2012) 1.64
Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res (2006) 1.63
The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci (2009) 1.62
Beyond audiofacial morbidity after vestibular schwannoma surgery. J Neurosurg (2009) 1.59
Treatment-related morbidity and the management of pediatric craniopharyngioma: a systematic review. J Neurosurg Pediatr (2012) 1.57
Intratumoral hemorrhage and fibrosis in vestibular schwannoma: a possible mechanism for hearing loss. J Neurosurg (2010) 1.55
Frequency and predictors of complications in neurological surgery: national trends from 2006 to 2011. J Neurosurg (2013) 1.55
Atypia predicting prognosis for intracranial extraventricular neurocytomas. J Neurosurg (2011) 1.54
Extent of resection and the long-term durability of vestibular schwannoma surgery. J Neurosurg (2011) 1.53
Risk factors for the development of serious medical complications after resection of meningiomas. Clinical article. J Neurosurg (2010) 1.53
Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res (2006) 1.52
Tumor control after surgery for spinal myxopapillary ependymomas: distinct outcomes in adults versus children: a systematic review. J Neurosurg Spine (2013) 1.51
Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma. J Neurosurg (2015) 1.48
Prevalence of previous extracranial malignancies in a series of 1228 patients presenting with meningioma. J Neurosurg (2010) 1.48
Gliomas: advances in molecular analysis and characterization. Surg Neurol (2005) 1.46
A prospective study of hearing preservation in untreated vestibular schwannomas. J Neurosurg (2010) 1.46
What clinical factors predict the incidence of deep venous thrombosis and pulmonary embolism in neurosurgical patients? J Neurosurg (2014) 1.44
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol (2009) 1.43
Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg (2010) 1.38
From the notch to a glioma grading system: the neurological contributions of James Watson Kernohan. Neurosurg Focus (2014) 1.38
Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol (2012) 1.38
Intracranial hemangiopericytoma: clinical experience and treatment considerations in a modern series of 40 adult patients. Cancer (2011) 1.35
Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother (2009) 1.33
The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus (2011) 1.33
Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg (2009) 1.32
Predictors of mortality following treatment of intracranial hemangiopericytoma. J Neurosurg (2010) 1.28
Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology (2010) 1.28
CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci (2010) 1.26
Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol (2009) 1.25
Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg (2005) 1.25
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol (2013) 1.25
Changes in transcranial motor evoked potentials during intramedullary spinal cord tumor resection correlate with postoperative motor function. Neurosurgery (2005) 1.24
Taking ecological function seriously: soil microbial communities can obviate allelopathic effects of released metabolites. PLoS One (2009) 1.22
Immunoprotective sertoli cells: making allogeneic and xenogeneic transplantation feasible. Reproduction (2009) 1.18
Human immunodeficiency virus type 1 envelope gp120 induces a stop signal and virological synapse formation in noninfected CD4+ T cells. J Virol (2008) 1.16
Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res (2012) 1.15
The complement cascade as a mediator of tissue growth and regeneration. Inflamm Res (2010) 1.14